340 related articles for article (PubMed ID: 12269713)
1. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
Hung JC; Augustine SC; Cheng KT; Green RL; Hopkins WM; Laven DL; Nelson BR; Petry NA; Ponto JA; Quinton TM; Swanson DP
J Am Pharm Assoc (Wash); 2002; 42(5):789-98. PubMed ID: 12269713
[TBL] [Abstract][Full Text] [Related]
2. Regulation of the compounding of positron emission tomography drugs.
Hung JC
Am J Health Syst Pharm; 2001 Jan; 58(2):134-9. PubMed ID: 11202536
[TBL] [Abstract][Full Text] [Related]
3. Compounding botanicals: a legal perspective.
Valentino JG; Bormel FG
J Am Pharm Assoc (Wash); 1999; 39(4):537-44. PubMed ID: 10467820
[TBL] [Abstract][Full Text] [Related]
4. Applying Quality by Design Concepts to Pharmacy Compounding.
Timko RJ
Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
[TBL] [Abstract][Full Text] [Related]
5. Comparison of various requirements of the quality assurance procedures for (18)F-FDG injection.
Hung JC
J Nucl Med; 2002 Nov; 43(11):1495-506. PubMed ID: 12411554
[TBL] [Abstract][Full Text] [Related]
6. Final guidance for pharmacy compounding of human drug products under Section 503A.
Blankenship CE
Int J Pharm Compd; 2014; 18(5):379-80. PubMed ID: 25577886
[No Abstract] [Full Text] [Related]
7. Pharmacy compounding of high-risk level products and patient safety.
Mullarkey T
Am J Health Syst Pharm; 2009 Sep; 66(17 Suppl 5):S4-13. PubMed ID: 19710449
[TBL] [Abstract][Full Text] [Related]
8. Compounding for animal patients: contemporary issues.
Lust E
J Am Pharm Assoc (2003); 2004; 44(3):375-84; quiz 384-6. PubMed ID: 15191248
[TBL] [Abstract][Full Text] [Related]
9. Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance.
Greeson NM; Mixon W; Allan WC
Int J Pharm Compd; 2020; 24(5):371-379. PubMed ID: 32886634
[TBL] [Abstract][Full Text] [Related]
10. Operation of a radiopharmacy for a clinical trial.
Norenberg JP; Petry NA; Schwarz S
Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
[TBL] [Abstract][Full Text] [Related]
11. Potential risks of pharmacy compounding.
Gudeman J; Jozwiakowski M; Chollet J; Randell M
Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
[TBL] [Abstract][Full Text] [Related]
12. Compounding pharmacy conundrum: "we cannot live without them but we cannot live with them" according to the present paradigm.
Guharoy R; Noviasky J; Haydar Z; Fakih MG; Hartman C
Chest; 2013 Apr; 143(4):896-900. PubMed ID: 23412546
[TBL] [Abstract][Full Text] [Related]
13. U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies.
Yoch D
Int J Pharm Compd; 2017; 21(2):95-102. PubMed ID: 28346203
[TBL] [Abstract][Full Text] [Related]
14. Medical Device; exemption from premarket notification; class II devices; pharmacy compounding systems. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2001 Mar; 66(55):15796-8. PubMed ID: 11706859
[TBL] [Abstract][Full Text] [Related]
15. Records and record-keeping for the hospital compounding pharmacist.
McElhiney LF
Int J Pharm Compd; 2007; 11(2):136-41. PubMed ID: 23974620
[TBL] [Abstract][Full Text] [Related]
16. Current good manufacturing practice for positron emission tomography drugs.
Food and Drug Administration, HHS
Fed Regist; 2009 Dec; 74(236):65409-36. PubMed ID: 20169678
[TBL] [Abstract][Full Text] [Related]
17. Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines.
Allen LV
Int J Pharm Compd; 2016; 20(4):351. PubMed ID: 28333682
[No Abstract] [Full Text] [Related]
18. Laboratory considerations of United States Pharmacopeia Chapter <71> sterility tests and its application to pharmaceutical compounding.
Hyde TD
Int J Pharm Compd; 2014; 18(1):46-52. PubMed ID: 24881341
[TBL] [Abstract][Full Text] [Related]
19. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule.
Fed Regist; 1999 Mar; 64(44):10944-7. PubMed ID: 10557618
[TBL] [Abstract][Full Text] [Related]
20. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring--FDA. Proposed rule.
Fed Regist; 1998 May; 63(99):28301-9. PubMed ID: 10179873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
